ORIGINAL RESEARCH article
Front. Oncol.
Sec. Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1613697
Comparison of Albumin-Bilirubin (ALBI), Platelet-Albumin-Bilirubin (PALBI), and Child-Pugh (CP) scores to predict overall survival in patients with stage C hepatocellular carcinoma with liver cirrhosis treated with c-TACE
Provisionally accepted- The Affiliated Hospital of Southwest Medical University, Luzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Purpose: This study aimed to evaluate and compare the prognostic performance of Albumin-Bilirubin (ALBI), Platelet-Albumin-Bilirubin (PALBI), and Child-Pugh (CP) scores in predicting overall survival (OS) among patients with stage C hepatocellular carcinoma (HCC) with liver cirrhosis undergoing conventional transcatheter arterial chemoembolization (c-TACE). Methods: We performed a retrospective cohort analysis of 151 cirrhotic patients with Barcelona Clinic Liver Cancer (BCLC) stage C HCC treated with c-TACE between 2017 and 2021. Pretreatment CP scores, ALBI, and PALBI were recorded, and their associations with OS were analyzed using Kaplan-Meier methods and receiver operating characteristic (ROC) curve analysis.Multivariate Cox models were used to determine independent survival predictors.The median OS for the entire study cohort was 18.8 months (95% CI: 11.294-26.306 months). CP score, ALBI grade and PALBI grade were significantly correlated with OS (all P<0.05). Survival analysis revealed dose-dependent relationships: CP classes A and B demonstrated median OS of 22.9 vs 9.9 months (P<0.05), ALBI grades 1-3 corresponded to median OS of 25.7, 12.7, and 3.8 months respectively (P<0.05), PALBI grades 1-3 showed median OS of 25.7, 10.1, and 8.5 months (P<0.05). The area under the receiver operating characteristic curve (AUROC) values of CP score, ALBI grading, ALBI score, PALBI grading and PALBI score were 0.572, 0.550, 0.595, 0.619 and 0.637, respectively. Compared with the CP score and ALBI, PALBI showed a better predictive effect in patients with stage C hepatocellular carcinoma with cirrhosis treated with c-TACE. Multivariate analysis showed that CP grade, ALBI grade, PALBI grade, Portal vein invasion, and the number of c-TACE were independent predictors affecting the survival period of patients. Conclusion: In cirrhotic patients with BCLC stage C HCC undergoing c-TACE, the PALBI scoring system emerged as a more reliable prognostic indicator than CP and ALBI assessments, showing enhanced discriminative capacity for survival outcomes.
Keywords: Hepatocellular Carcinoma, Liver Cirrhosis, PALBI, AlBi, Child-Pugh
Received: 17 Apr 2025; Accepted: 08 Aug 2025.
Copyright: © 2025 Wu, Zhang and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Shanshan Liu, The Affiliated Hospital of Southwest Medical University, Luzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.